

Comparison of Genotypic Resistance Pattern Between *Enterococcus faecium* and *Enterococcus faecalis* to Better Understand Selection of Antibiotics For Treatment Purposes.

Sowmya Padakanti DO¹; Vismay Badhiwala MD¹; Munok Hwang MS²; Hosoon Choi PhD²; Piyali Chatterjee PhD²; Sorabh Dhar, MD⁵; Keith Kaye MD, MPH³; Chetan Jinadatha MD, MPH²


¹Baylor Scott & White Medical Center | ²Central Texas Veterans Health Care System | ³Robert Wood Johnson Medical School | ⁴Detroit Medical Center | ⁵John D. Dingell VA Medical Center

BACKGROUND

Enterococcus is one of the major causes of nosocomial infections, many with vancomycin resistance. About 50,000 infections are reported per year due to vancomycin-resistant *Enterococci* (VRE). VRE variants can be challenging to manage and has been shown to increase cost and mortality rates. Understanding the genotypic mutations can help recognize the potential burden for antibiotic resistance that exists in a population and guide in antibiotic selection. In this study, using whole genome sequencing (WGS) we aim to analyze the prevalence of genetic resistance markers for commonly used antibiotics for *Enterococcal* treatment.

METHODS

Whole genome sequencing was performed using the NextSeq (Illumina Inc., CA) on 60 isolates of *E. faecium* and 29 isolates of *E. faecalis*. The isolates were obtained from two different Detroit area hospitals from 2017-2019. The data from WGS was analyzed using EPISQ CS™ (BIOMÉRIEUX, Marcy l’Etoile, France) bioinformatic database to obtain specific resistance genes which would correspond to commonly used antibiotics for treatment of *Enterococcal* infections.



RESULTS

Among the 89 *Enterococcus faecium* and *E. faecalis* investigated, we identified a total of 33 unique resistance genes across 16 classes of antibiotics (Table 1). The most common antibiotic classes include aminoglycosides, tetracyclines, quinolones, beta-lactams, glycopeptides, macrolides, and pyrimidine analogs. *E. faecium* and *E. faecalis* share 14 similar resistance genes from 10 classes of antibiotics. *E. faecium* has more number of unique resistance genes when compared to *E. faecalis* (Table 2). *E. faecium* has resistance genes covering all drug classes except for Acridine, whereas *E. faecalis* has resistance genes excluding Beta-lactams and Nitromidazole drug class (Table 1).

CONCLUSION

Enterococcus faecium had a greater number of resistance genes with glycopeptide, aminoglycoside, and beta lactam drugs when compared to *Enterococcus faecalis*. Whereas *Enterococcus faecalis* had more resistance genes associated with macrolides, tetracyclines, pyrimidine analogs, and Bactrim. In general, both appear to have many genes that encode for resistance to major classes of antibiotics which are used for treatment of *Enterococcal* infections. Further comparison with phenotypic susceptibility testing data would help better understand the practical implications of our resistance gene testing.

REFERENCES

Arias CA, Murray BE. The rise of the *Enterococcus*: beyond vancomycin resistance. *Nat Rev Microbiol.* 2012;10:266–78.
 Joseph W. Chow, Aminoglycoside Resistance in *Enterococci*, *Clinical Infectious Diseases*, Volume 31, Issue 2, August 2000, Pages 586–589, <https://doi.org/10.1086/313949>
 Lee, Terence et al. "Antimicrobial-resistant CC17 *Enterococcus faecium*: The past, the present and the future." *Journal of global antimicrobial resistance* vol. 16 (2019): 36-47. doi:10.1016/j.jgar.2018.08.016
 Miller, William R et al. "Mechanisms of antibiotic resistance in enterococci." *Expert review of anti-infective therapy* vol. 12,10 (2014): 1221-36. doi:10.1586/14787210.2014.956092

Acknowledgements: Funding for this project was supported by AHRQ #R01HS24709 (PI: Keith Kaye). Additional support was also provided by the Central Texas Veterans Healthcare System (CTVHCS) facility during the study period.


ANTIBIOTIC RESISTANCE

Drug class resistance	<i>E. faecium</i> (n=60)	<i>E. faecalis</i> (n=29)
	Genes	
Aminoglycosides	aac(6')-I, aac(6')-II, ant(9)-Ia aad(6), aacA/aphD, aph(3')-IIIa sat4	aad(6) aacA/aphD, aph(3')-IIIa sat4
Nucleoside	Sat4 efmA	Sat4
Pyrimidine analogs	dfrG	dfrC, dfrE dfrG
Trimethoprim/sulfonamides	dfrG	dfrC, dfrE dfrG
<i>Pleuromutilins</i>	eat(A)	isa(A)
Acridine		emeA
Quinolones	efmA tet(L)	emeA
Tetracyclines	efmA msrC tet(M) tet(S) tet(L)	emeA tet(M) isa(A)
Beta-lactams	efmA pbp5 tet(L)	
Macrolides	efmA msrC erm(A) erm(B)	erm(B) erm(C) isa(A)
lincosamides	efmA msrC erm(A) erm(B) tet(L)	erm(B) erm(C) isa(A)
streptogramins	efmA msrC erm(A) erm(B) tet(L)	erm(B) erm(C) isa(A)
Nitroimidazole	efmA tet(L)	
Peptides	efmA liaS erm(A) erm(B)	erm(B) erm(C)
Glycopeptides	vanA, vanR, vanS, vanX-A, vanY-A vanZ-A, vanH-A	vanA, vanR, vanS, vanX-A, vanY-A vanZ-A, vanH-A

Green = both
 Yellow = *E. faecium*
 Red = *E. faecalis*
 Table 1. *Enterococcus faecium* and *E. faecalis* genetic mutations and drug class resistance

	<i>E. Faecium</i>	<i>E. Faecalis</i>
# of Unique Resistance genes	12	7
Unique drug classes	efmA, pbp5, tet(L), liar, liaS	emeA

Table 2: Comparison of mutations unique to *Enterococcus faecium* and *E. faecalis*



Gram-positive facultative anaerobic cocci in short and medium chains
Enterococcus faecium and *E. faecalis*

